What is Leerink Partnrs’ Forecast for OKUR FY2024 Earnings?

OnKure Therapeutics (NASDAQ:OKUR) – Equities research analysts at Leerink Partnrs issued their FY2024 earnings estimates for shares of OnKure Therapeutics in a research note issued on Thursday, December 5th. Leerink Partnrs analyst A. Berens forecasts that the company will post earnings of ($3.89) per share for the year. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for OnKure Therapeutics’ current full-year earnings is ($4.05) per share. Leerink Partnrs also issued estimates for OnKure Therapeutics’ Q4 2024 earnings at ($1.10) EPS, FY2025 earnings at ($4.31) EPS, FY2026 earnings at ($3.19) EPS, FY2027 earnings at ($3.91) EPS and FY2028 earnings at ($3.65) EPS.

OnKure Therapeutics (NASDAQ:OKUR) last released its earnings results on Thursday, November 7th. The company reported ($1.10) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.13).

OKUR has been the subject of several other research reports. HC Wainwright reissued a “buy” rating and set a $40.00 target price on shares of OnKure Therapeutics in a report on Friday, November 8th. Lifesci Capital raised OnKure Therapeutics to a “strong-buy” rating in a report on Thursday, October 10th. Oppenheimer assumed coverage on OnKure Therapeutics in a report on Thursday, October 10th. They set an “outperform” rating and a $35.00 target price on the stock. Finally, Leerink Partners initiated coverage on OnKure Therapeutics in a report on Thursday, December 5th. They set an “outperform” rating and a $33.00 target price on the stock. Three equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $36.00.

OnKure Therapeutics Stock Performance

NASDAQ:OKUR opened at $13.73 on Monday. The stock has a market cap of $45.90 million, a P/E ratio of -1.13 and a beta of 0.14. OnKure Therapeutics has a twelve month low of $9.80 and a twelve month high of $77.60. The stock’s 50 day moving average is $16.73.

About OnKure Therapeutics

Reneo Pharmaceuticals Incis a clinical stage pharmaceutical company. It is focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases. Reneo Pharmaceuticals Incis based in SAN DIEGO.